<DOC>
	<DOCNO>NCT01197378</DOCNO>
	<brief_summary>Cystinosis inherit disease untreated , result kidney failure early first decade life . The current marketed therapy Cystagon® ( cysteamine bitartrate ) must take every six hour rest patient 's life prevent complication cystinosis . RP103 formulation cysteamine bitartrate study see may able give less frequently , every 12 hour , similar result four time day Cystagon® .</brief_summary>
	<brief_title>Long-Term Safety Follow-up Study Cysteamine Bitartrate Delayed-release Capsules ( RP103 )</brief_title>
	<detailed_description>This long-term , open-label , study determine safety tolerability twice day treatment Cysteamine Bitartrate Delayed-release Capsules ( RP103 ) . It involve 6-9 monthly clinic visit follow quarterly clinic visit duration study home use RP103 . Enrollment offer first patient complete previous Phase 3 Study ( RP103-03 , NCT01000961 ) wo n't offer others data analysis RP103-03 subject complete .</detailed_description>
	<mesh_term>Cystinosis</mesh_term>
	<mesh_term>Cysteamine</mesh_term>
	<criteria>Male female subject must complete last visit Study RP10303 willing continue RP103 treatment . OR patient complete RP10303 study : Male female subject must cystinosis . Subjects must stable dose Cystagon® least 21 day prior Screening . Within last 6 month , clinically significant change normal liver function test [ i.e. , ALT , AST , total bilirubin ] renal function [ i.e. , estimate GFR ] Screening determine Investigator . Subjects estimate GFR ( correct body surface area ) &gt; 30 mL/min/1.73m2 . Sexually active female subject childbearing potential ( i.e. , surgically sterile [ tubal ligation , hysterectomy , bilateral oophorectomy ] least 2 year naturally postmenopausal ) must agree utilize acceptable form contraception Screening completion study . Subjects must willing able comply study restriction requirement . Subjects parent guardian must provide write informed consent assent ( applicable ) prior participation study . Patients enrol previous Study RP10303 complete last schedule Study visit wish continue treatment RP103 . AND patient complete RP10303 study : Subjects less 1 year old Subjects know history , currently follow condition health issue make , opinion investigator , unsafe participate : inflammatory bowel disease ( currently active ) prior resection small intestine ; Heart disease ( e.g. , myocardial infarction , heart failure , unstable arrhythmia poorly control hypertension ) 90 day prior Screening ; Active bleed disorder 90 day prior Screening ; Malignant disease within last 2 year . Patients hemoglobin level &lt; 10 g/dL Screening level , opinion investigator , make unsafe subject participate . Subjects know hypersensitivity cysteamine penicillamine . Female subject nursing , plan pregnancy , know suspected pregnant , positive serum pregnancy screen . Subjects , opinion Investigator , able willing comply protocol .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>cystinosis</keyword>
	<keyword>cysteamine</keyword>
	<keyword>inheritable disease</keyword>
	<keyword>orphan disease</keyword>
	<keyword>CTNS protein , human</keyword>
	<keyword>metabolic disease</keyword>
	<keyword>nephropathic cystinosis</keyword>
</DOC>